Erratum To: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Cardiology and Therapy
doi 10.1007/s40119-016-0070-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View

2020English

Exploring Novel Pharmacotherapeutic Applications and Repurposing Potential of Sodium Glucose CoTransporter 2 (SGLT2) Inhibitors

Clinical and Experimental Pharmacology and Physiology
PhysiologyPharmacology
2018English

Use of Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections in Type 2 Diabetes Patients: A Systematic Review

Revista da Associacao Medica Brasileira
Medicine
2019English

Differential Cardiovascular Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: Critical Evaluation of Empagliflozin

Therapeutics and Clinical Risk Management
2017English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells

PLoS ONE
Multidisciplinary
2016English

Fournier’s Gangrene and Sodium-Glucose Cotransporter-2 Inhibitors: Is There a Causal Association?

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy